Following the recruitment of Emeline Ragonnaud, who joined the team from NIH in June this year, Hervolution is now delighted to announce the award of a postdoctoral grant from Innovation Fund Denmark for her project.
The grant has a 3-year perspective and allows Hervolution to establish strategic collaborations with key people within each of their fields. One of them is Sharon Glynn (in the picture) from the National University of Ireland, Galway. She is an established researcher within the role of HERV-K in human cancers.
“I’m delighted to be collaborating with Hervolution on developing new therapeutics targeting HERV-K. My lab at NUI Galway has been working on HERV-K in breast and prostate cancer and we believe it is a promising target,” says Sharon Glynn.
Apart from Sharon Glynn, the grant allows Hervolution to collaborate with Frederik Otzen Bagger, Head of Bioinformatics at Rigshospitalet (Copenhagen University Hospital), and Cathrine Ørskov who runs the Histology laboratory at the University of Copenhagen.
According to Hervolution’s CEO Peter J. Holst, Emeline’s project and the new collaborations will allow the company to position its HERV-K directed immunotherapies in the human cancer space.
“Having a postdoc grant allows us to make a long-term research and development plan that is attractive to key academic partners. This project now provides access to key competencies in morphological studies, bioinformatics, and one the world’s leading translational researchers into HERVs in human cancers.”